Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus

Because radioactive raclopride and radioactive (+)‐4‐propyl‐9‐hydroxynaphthoxazine ((+)‐PHNO) are used to image dopamine (DA) D2 and D3 receptors in the striatum and globus pallidus in humans, the present study examined the proportions of D2 and D3 receptors in postmortem tissues from these regions. Conflicting results were obtained when using a single concentration of remoxipride to occlude D2 receptors or using a single concentration of U99194A or FAUC 365 to occlude D3 receptors. However, using a range of concentrations of FAUC 365, a D3‐selective antagonist, to inhibit the binding [3H]raclopride or [3H]‐(+)‐PHNO to D3 receptors at low concentrations (1–10 nM) and to inhibit ligand binding to D2 receptors at higher concentrations (100–2000 nM), it was possible to measure the proportion of D2 and D3 receptors in the tissues. This method revealed that these two radioligands detected only D2 receptors in the dorsal putamen and the dorsal caudate nucleus, but detected a mixed population of two‐thirds D2 and one‐third D3 DA receptors in the ventral putamen, the ventral caudate, and the globus pallidus. The present findings are in good agreement with the known gene expression data for D2 and D3 receptors in these human brain regions. Synapse 60:205–211, 2006. © 2006 Wiley‐Liss, Inc.

[1]  P. Seeman.  An update of fast-off dopamine D2 atypical antipsychotics. , 2005, The American journal of psychiatry.

[2]  P. Seeman,et al.  Dopamine displaces [3H]domperidone from high‐affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography , 2003, Synapse.

[3]  L. W. Cooke,et al.  Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. , 1995, The Journal of pharmacology and experimental therapeutics.

[4]  J. Meador-Woodruff,et al.  Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into Schizophrenia , 1997, Neuropsychopharmacology.

[5]  P. Seeman,et al.  Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. , 1995, European journal of pharmacology.

[6]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[7]  SB-277011 GlaxoSmithKline. , 2001, Current opinion in investigational drugs.

[8]  J. Palacios,et al.  High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review. , 2012, Analytica chimica acta.

[9]  J. W. Wells,et al.  Dopamine Receptor Parameters Detected by [3H]Spiperone Depend on Tissue Concentration: Analysis and Examples , 1984, Journal of neurochemistry.

[10]  G. Vauquelin,et al.  Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin , 1994, Brain Research.

[11]  Lars Farde,et al.  Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907 , 1996, Psychopharmacology.

[12]  K. Davis,et al.  Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. , 1997, Archives of general psychiatry.

[13]  J. Joyce,et al.  D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period , 2001, Synapse.

[14]  N. Ginovart,et al.  Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2high and D3high receptors , 2005, Synapse.

[15]  P. Seeman.  Antipsychotic drugs, dopamine receptors, and schizophrenia , 2001, Clinical Neuroscience Research.

[16]  G. Sedvall,et al.  Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.

[17]  Philip Seeman,et al.  Atypical Antipsychotics: Mechanism of Action , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[18]  S. Kapur,et al.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.

[19]  D. Sibley,et al.  [3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. , 1995, European journal of pharmacology.

[20]  P. Seeman,et al.  Dopamine Displaces [ 3 H ] Domperidone From High-Affinity Sites of the Dopamine D 2 Receptor , But Not [ 3 H ] Raclopride or [ 3 H ] Spiperone in Isotonic Medium : Implications for Human Positron Emission Tomography , 2003 .

[21]  Y. Lecrubier.  S.27.02 A partial D3 receptor agonist in schizophrenia , 2003, European Neuropsychopharmacology.

[22]  J. Joyce,et al.  Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Seeman,et al.  The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase. , 2000, Brain research. Molecular brain research.

[24]  J. Hagan,et al.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.

[25]  P. Molinoff,et al.  Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors , 1995, Neuropsychopharmacology.

[26]  Sylvain Houle,et al.  High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO , 2006, Biological Psychiatry.

[27]  M. Millan,et al.  Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.

[28]  M. Martres,et al.  Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.

[29]  Sylvain Houle,et al.  Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. , 2005, Journal of medicinal chemistry.

[30]  M. Millan,et al.  A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. , 1998, The Journal of pharmacology and experimental therapeutics.

[31]  R. Gur,et al.  Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. , 1997, Archives of general psychiatry.

[32]  Harald Hübner,et al.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. , 2002, Journal of medicinal chemistry.

[33]  P. Seeman,et al.  Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. , 1999, The American journal of psychiatry.